MorphoSys AG (OTCMKTS:MPSYF) Sees Large Decline in Short Interest

MorphoSys AG (OTCMKTS:MPSYFGet Rating) saw a large decrease in short interest in August. As of August 31st, there was short interest totalling 674,300 shares, a decrease of 12.0% from the August 15th total of 766,400 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 6,743.0 days.

MorphoSys Trading Down 11.8 %

MPSYF stock opened at $16.25 on Monday. MorphoSys has a 12-month low of $15.67 and a 12-month high of $49.20. The company has a 50 day moving average of $20.05 and a two-hundred day moving average of $22.06.

About MorphoSys

(Get Rating)

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

Featured Articles

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.